KLRB1 and neoplasm: Numbers of tumor-infiltrating CD4+ cells were not associated with disease-specific survival (DSS), but subgrouping patients based on CD4+CD161+ Tem numbers resulted in a clear separation of survival curves with increased DSS for the group of patients with high CD4+CD161+ Tem levels.